Posts

Posted on

ADM, InnovaFeed announce construction of world’s largest insect protein facility in Decatur, Illinois

ADM, InnovaFeed announce construction of world’s largest insect protein facility in Decatur, Illinois

  • New project represents innovative, sustainable production to meet growing demand for insect protein in animal feed, a market that has potential to reach 1 million tons in 2027
  • Construction of high-capacity facility to support hundreds of jobs in Decatur area, targeted to begin in 2021, pending permits and approvals

CHICAGO & PARIS–(BUSINESS WIRE)–
ADM (NYSE:ADM), one of the world’s leading human and animal nutrition providers, and InnovaFeed, the world leader in producing premium insect ingredients for animal feed, today announced plans to collaborate on the construction and operation of the world’s largest insect protein production site, in Decatur, Illinois. The facility will be owned and operated by InnovaFeed and will co-locate with ADM’s Decatur corn processing complex, with ADM supplying feedstocks, waste heat and more. Together, these investments will bolster economic growth and job creation in Decatur and central Illinois while continuing to strengthen the state’s position as a center of innovative, sustainable agriculture.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20201119005699/en/

“We are very pleased to launch this ambitious project, working alongside ADM and Illinois state partners as InnovaFeed expands to provide sustainable solutions to meet the fast growing demand for insect feed in the US and worldwide,” said Clement Ray, CEO and co-founder of InnovaFeed. “Around the world, InnovaFeed is contributing to the emergence of sustainable food systems by developing a pioneering and sustainable industry. Our new operations in Illinois, a global leader and destination for agriculture, will allow us to take the next steps to innovate and grow our business.”

“At a time when the demand for animal feed protein is steadily increasing, insect farming stands out as a true solution for the future,” said Chris Cuddy, ADM senior vice president and president of the company’s Carbohydrate Solutions business. “We’re excited to work with InnovaFeed on this ambitious project, which further expands our participation in the growing market for animal food and feed that comes from responsible, sustainable sources. It’s a great demonstration of how ADM is expanding its value chain by offering opportunities for collaboration to leading, innovative startups. It’s yet another example of how we’re constantly identifying new ways to create value from corn, oilseeds and more. And of course, we’re extremely proud that we can help bring this new, job-creating project to Decatur, the home of our North American headquarters.”

Insect feed has become an increasingly popular protein ingredient for the agriculture and aquaculture industries, as demand for animal feed has now reached an all-time high and consumers look for food that is sustainably and responsibly grown. InnovaFeed already operates two insect production facilities in France, including what is today the world’s largest. The Decatur facility represents InnovaFeed’s first international project.

“InnovaFeed’s decision to bring their first ever international facility and state-of-the-art agriculture technology to Illinois is a vote of confidence for our state, and a win for our farming communities,” said Governor JB Pritzker. “Illinois has always been a global leader in agriculture and technology, and we offer the resources to support this major international expansion – with an educated workforce, proximity to global businesses like ADM, and access to shipping and logistics. The investments InnovaFeed is making in Decatur will not only support our thriving agriculture industry – a cornerstone of our economy – but will unlock new well-paying jobs for our communities.”

Construction of the new high-capacity facility is expected to create more than 280 direct and 400 indirect jobs in the Decatur region by the second phase. The Illinois Department of Commerce and Economic Opportunity (DCEO) and the Illinois workNet Center will partner with InnovaFeed to develop recruiting strategies as well as on-the-job training programs. DCEO also partnered with InnovaFeed through an EDGE agreement to support this large-scale capital investment. Locally, InnovaFeed will benefit from the Decatur-Macon County Enterprise Zone and customized incentive opportunities from the City of Decatur and Economic Development Corporation of Decatur-Macon County.

Construction is targeted to begin in 2021, pending necessary permitting and approvals. Construction and production will come in two phases. When both are complete, the plant would have a target annual production capacity of 60,000 metric tons of animal feed protein derived from Hermetia Illucens, a type of fly with exceptional nutritional qualities; the plant will also have the capability to produce 20,000 metric tons every year of oils for poultry and swine rations, and 400,000 metric tons of fertilizer.

“Illinois remains open for business, and companies continue to choose Illinois for growth based on our industry strengths, talent, education and access to infrastructure,” said Illinois Department of Commerce & Economic Opportunity Director Erin Guthrie. “With agriculture a leading industry and employer for communities across our state, these investments by InnovaFeed to bring their one-of-a-kind technology will support our farmers and those who rely upon farms. We look forward to partnering with the company on ensuring our local residents have access to jobs and economic opportunity created by this exciting new project in Decatur.”

“The city of Decatur is pleased to partner with InnovaFeed to bring this unique and innovative facility to our community,” said Decatur Mayor Julie Moore Wolfe. “Not only will this project fuel both direct and indirect job creation, but it affirms that our best prospects for creating new jobs are in the agri-business sector, in partnership with our existing businesses, in a city that is an ideal place for groundbreaking advanced manufacturing. ADM, the State of Illinois, the Economic Development Corporation of Decatur-Macon County, and the City of Decatur worked together to bring this plant to Decatur. Our concierge approach results in joint incentive opportunities to support InnovaFeed’s infrastructure and operational needs.”

The plant will be built using an innovative model of industrial collaboration that InnovaFeed has already demonstrated in other facilities enabling the French Biotech company to produce the insect protein with the lowest carbon footprint on the market. The plant will be co-located with ADM’s Decatur corn complex, with complementary infrastructure that will allow ADM to directly provide corn by-products to supply InnovaFeed’s innovative insect rearing process, as well as waste heat and steam. This collaborative operational model will enable the InnovaFeed facility to reduce CO2 emissions by 80 percent versus standalone production.

About ADM

At ADM, we unlock the power of nature to provide access to nutrition worldwide. With industry-advancing innovations, a complete portfolio of ingredients and solutions to meet any taste, and a commitment to sustainability, we give customers an edge in solving the nutritional challenges of today and tomorrow. We’re a global leader in human and animal nutrition and the world’s premier agricultural origination and processing company. Our breadth, depth, insights, facilities and logistical expertise give us unparalleled capabilities to meet needs for food, beverages, health and wellness, and more. From the seed of the idea to the outcome of the solution, we enrich the quality of life the world over. Learn more at www.adm.com.

About InnovaFeed

InnovaFeed is a biotech company that produces a new source of protein from insect rearing (Hermetia Illucens) for animal and plant nutrition. InnovaFeed’s mission is to participate in the rise of sustainable food systems by addressing the increasing demand for natural, healthy and competitive raw materials. Combining the largest production capacity on the market and state of the art research in biotechnology, InnovaFeed has developed an innovative technology and process enabling the production of high-quality insect ingredients at industrial scale and at a competitive price.

www.innovafeed.com

Source: Corporate Release

Press contacts:

For InnovaFeed: Marianne Rageot, +337 78 21 51 09, [email protected]

For ADM: Jackie Anderson, 312-634-8484, [email protected]

For State of Illinois: Lauren Huffman, 217-622-0435, [email protected]

For Economic Development Corporation of Decatur-Macon County: Nicole Bateman, 217-369-1509, [email protected]

KEYWORDS: Europe United States North America France Illinois

INDUSTRY KEYWORDS: Biotechnology Retail Chemicals/Plastics Health Other Energy Manufacturing Public Policy/Government Alternative Energy Energy Supermarket Agriculture Natural Resources State/Local Food/Beverage

MEDIA:

Logo
Logo
Logo
Logo
Posted on

VBI Vaccines Announces Positive Interim Phase 2a Data from VBI-1901 in Recurrent GBM

VBI Vaccines Announces Positive Interim Phase 2a Data from VBI-1901 in Recurrent GBM

– Interim data show promising disease control rates in patients vaccinated with VBI-1901 combined with the GM-CSF adjuvant (40%), and with VBI-1901 combined with GSK’s adjuvant AS011 (56%)

– 2 partial responses observed in VBI-1901 + GM-CSF study arm, with tumor reduction of more than 50%, and 7 stable disease observations across both vaccinated groups

– VBI-1901 was well-tolerated with both adjuvants – no safety signals observed in either vaccinated group

CAMBRIDGE, Mass.–(BUSINESS WIRE)–
VBI Vaccines Inc. (Nasdaq: VBIV) (“VBI”) a commercial-stage biopharmaceutical company developing next-generation infectious disease and immuno-oncology vaccines, today announced Phase 2a (Part B) data from its ongoing Phase 1/2a study of VBI-1901, the company’s cancer vaccine immunotherapeutic candidate designed to target cytomegalovirus (CMV) as a foreign viral antigen in recurrent glioblastoma (GBM). The data were presented in an e-poster at the Society for Neuro-Oncology (SNO) 2020 Annual Meeting, November 19-21, 2020.

Data from Phase 2a (Part B) of the ongoing study showed:

  • 2 partial responses (PRs) and 2 stable disease (SD) observed in the VBI-1901 + GM-CSF vaccinated group, resulting in a disease control rate of 40% (n=4/10)
  • A 56% disease control rate achieved in the group vaccinated with VBI-1901 + AS01, with 5 stable disease observations (n=5/9) – tumor response data for the 10th patient enrolled is pending
  • Presumed pseudoprogression was observed in both vaccinated groups– defined as immune infiltration into the tumor which appears initially as tumor growth, but later subsides resulting in tumor growth stabilization and/or shrinkage

Andrew B. Lassman, M.D., Chief of Neuro-oncology at Columbia University Irving Medical Center and Associate Director for Clinical Trials at the Herbert Irving Comprehensive Cancer Center, and principal investigator of the study presented the e-poster, commenting, “Tumor response data is one of the most objective measures of efficacy in open label studies, especially in this difficult-to-treat patient population. Few treatment options are available to recurrent glioblastoma patients, and the tumor response data seen to-date in this ongoing study are encouraging. Any treatment that could demonstrate clinical benefit would be incredibly meaningful.”

Emmanuel Hanon, Senior Vice President, Head of R&D Vaccines at GSK, commented, “The early data seen to-date in this ongoing study are encouraging, underscoring the potential benefit of adjuvants in combination with VBI-1901 in the clinical setting. Previous research in the context of other vaccines has shown AS01’s ability to boost T cell-mediated immunity. This is the first time GSK’s adjuvant system is assessed in oncology and we are looking forward to getting more data about the potential of therapeutic vaccination to treat such an aggressive and recurring disease.”

David E. Anderson, Ph.D., VBI’s Chief Scientific Officer, commented, “This ongoing study continues to demonstrate the potential of VBI-1901, with both the GM-CSF adjuvant and GSK’s AS01 adjuvant system, to be an effective cancer vaccine immunotherapeutic. The tumor responses seen to-date across both study arms, including 2 partial responses and 7 stable disease, are meaningful, especially as an outcome of a monotherapy. This data supports the continued development of the program, both as a monotherapy as well as part of a combination regimen.”

Based on the available data, VBI is exploring a randomized, controlled clinical study, including a potential registration study, for the next phase of development, which could begin in 2021, pending approval from regulatory bodies.

A webcast of Dr. Anderson discussing these data with Jeff Baxter, VBI’s President and CEO, can be found here: https://www.vbivaccines.com/wire/vbi-1901-sno-2020-update/.

A copy of the e-poster is available on the “Events/Presentations” page in the “Investors” section of the VBI Vaccines website.

About the Phase 1/2a Study Design

VBI’s two-part Phase 1/2a study is a multi-center, open-label, dose-escalation study of VBI-1901 in up to 38 patients with recurrent GBM:

  • Phase 1 (Part A)
    • Dose-escalation phase that defined the safety, tolerability, and optimal dose level of VBI-1901 adjuvanted with granulocyte-macrophage colony-stimulating factor (GM-CSF) in recurrent GBM patients with any number of prior recurrences.
    • This phase enrolled 18 recurrent GBM patients across three dose cohorts of VBI-1901: 0.4 µg, 2.0 µg, and 10.0 µg.
    • Enrollment completed in December 2018.
  • Phase 2a (Part B)
    • Subsequent extension of the optimal dose level, 10.0 µg, as defined in the Part A dose escalation phase.
    • This phase is a two-arm study, enrolling 10 first-recurrent GBM patients in each vaccinated group, assessing 10.0 µg of VBI-1901 in combination with either GM-CSF or GSK’s proprietary AS01 adjuvant system as immunomodulatory adjuvants.
    • Enrollment of the 10 patients in each adjuvant group is complete.

VBI-1901 is administered intradermally when adjuvanted with GM-CSF and intramuscularly when adjuvanted with GSK’s AS01 adjuvant system. Patients in both phases of the study receive the vaccine immunotherapeutic every four weeks until tumor progression.

About VBI-1901 and GBM

VBI-1901 is a novel cancer vaccine immunotherapeutic candidate developed using VBI’s enveloped virus-like particle (eVLP) technology to target two highly immunogenic cytomegalovirus (CMV) antigens, gB and pp65. Scientific literature suggests CMV infection is prevalent in multiple solid tumors, including glioblastoma (GBM). GBM is among the most common and aggressive malignant primary brain tumors in humans. In the U.S. alone, 12,000 new cases are diagnosed each year. The current standard of care for treating GBM is surgical resection, followed by radiation and chemotherapy. Even with aggressive treatment, GBM progresses rapidly and has a high mortality.

About VBI Vaccines Inc.

VBI Vaccines Inc. (Nasdaq: VBIV) is a commercial-stage biopharmaceutical company developing a next generation of vaccines to address unmet needs in infectious disease and immuno-oncology. VBI is advancing the prevention and treatment of hepatitis B, with the only 3-antigen hepatitis B vaccine, Sci-B-Vac®, which is approved for use and commercially available in Israel, and recently completed its Phase 3 program in the U.S., Europe, and Canada, and with an immunotherapeutic in development for a functional cure for chronic hepatitis B. VBI’s enveloped virus-like particle (eVLP) platform technology enables development of eVLPs that closely mimic the target virus to elicit a potent immune response. VBI’s lead eVLP programs include a vaccine immunotherapeutic candidate targeting glioblastoma (GBM), a prophylactic cytomegalovirus (CMV) vaccine candidate, and a prophylactic coronavirus vaccine program. VBI is headquartered in Cambridge, MA, with research operations in Ottawa, Canada, and research and manufacturing facilities in Rehovot, Israel.

Website Home: http://www.vbivaccines.com/

News and Insights: http://www.vbivaccines.com/wire/

Investors: http://www.vbivaccines.com/investors/

Cautionary Statement on Forward-looking Information

Certain statements in this press release that are forward-looking and not statements of historical fact are forward-looking statements within the meaning of the safe harbor provisions of the Private Securities Litigation Reform Act of 1995 and are forward-looking information within the meaning of Canadian securities laws (collectively, “forward-looking statements”). The Company cautions that such statements involve risks and uncertainties that may materially affect the Company’s results of operations. Such forward-looking statements are based on the beliefs of management as well as assumptions made by and information currently available to management. Actual results could differ materially from those contemplated by the forward-looking statements as a result of certain factors, including but not limited to, the impact of general economic, industry or political conditions in the United States or internationally; the impact of the recent COVID-19 outbreak on our clinical studies, manufacturing, business plan, and the global economy; the ability to establish that potential products are efficacious or safe in preclinical or clinical trials; the ability to establish or maintain collaborations on the development of therapeutic candidates; the ability to obtain appropriate or necessary governmental approvals to market potential products; the ability to obtain future funding for developmental products and working capital and to obtain such funding on commercially reasonable terms; the Company’s ability to manufacture product candidates on a commercial scale or in collaborations with third parties; changes in the size and nature of competitors; the ability to retain key executives and scientists; and the ability to secure and enforce legal rights related to the Company’s products. A discussion of these and other factors, including risks and uncertainties with respect to the Company, is set forth in the Company’s filings with the SEC and the Canadian securities authorities, including its Annual Report on Form 10-K filed with the SEC on March 5, 2020, and filed with the Canadian security authorities at sedar.com on March 5, 2020, as may be supplemented or amended by the Company’s Quarterly Reports on Form 10-Q. Given these risks, uncertainties and factors, you are cautioned not to place undue reliance on such forward-looking statements, which are qualified in their entirety by this cautionary statement. All such forward-looking statements made herein are based on our current expectations and we undertake no duty or obligation to update or revise any forward-looking statements for any reason, except as required by law.

1The GSK proprietary AS01 adjuvant system contains QS-21 StimulonTM adjuvant licensed from Agenus Inc. (NASDAQ: AGEN)

VBI

Nicole Anderson

Director, Corporate Communications & IR

Phone: (617) 830-3031 x124

Email: [email protected]

KEYWORDS: United States North America Massachusetts

INDUSTRY KEYWORDS: Research Infectious Diseases FDA Clinical Trials Other Health Biotechnology Pharmaceutical Health Science Oncology

MEDIA:

Logo
Logo
Posted on

Walgreens Reinvents Nation’s Largest Health and Wellbeing-centered Loyalty Program with myWalgreens to Offer Customers Many More Benefits

Walgreens Reinvents Nation’s Largest Health and Wellbeing-centered Loyalty Program with myWalgreens to Offer Customers Many More Benefits

One new benefit is the fastest, same-day retail pickup – in as little as 30 minutes

DEERFIELD, Ill.–(BUSINESS WIRE)–
Walgreens today announced the launch of myWalgreens, a complete reinvention of its customer loyalty program to offer customers extensive new benefits, including the fastest same-day retail pickup offering available today*. Customers can now shop online and on a fully-redesigned mobile app for health and wellness items, and then pick them up in the store, curbside or at the drive-thru in as little as 30 minutes.**

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20201119005676/en/

Walgreens pickup at curbside (Photo: Business Wire)

Walgreens pickup at curbside (Photo: Business Wire)

Walgreens has the nation’s largest health and wellbeing-centered customer loyalty program, with more than 100 million members. It’s now easier than ever for its members to stay well, shop conveniently and save money and time seamlessly across more than 9,000 stores, Walgreens.com and the mobile app.

The new benefits are in addition to many others already offered by Walgreens. These include an at-home delivery service through DoorDash and Postmates and a Prescription Savings Club with up to 80 percent off cash retail prices.

myWalgreens members can sign up quickly and easily for no cost, and will now receive:

  • One percent Walgreens Cash rewards storewide
  • Five percent Walgreens Cash rewards on Walgreens branded products
  • “Only for you” exclusive deals

Additionally, the mobile app now features a broad range of health and wellness services for customers and patients, including a 24/7 pharmacy chat, access to find and book medical care and vaccination appointments, personalized health and wellness advice, real-time flu alerts and more. The previous version of the app is already very popular, and has been downloaded more than 65 million times.

“As America’s community pharmacy, Walgreens is delivering an unparalleled experience to help customers and patients manage their health and wellbeing during the most severe health crisis of our lifetimes,” said John Standley, Walgreens president. “As always, our more than 25,000 community pharmacists remain at the core of our offering. Our pharmacists and patient care teams do far more than just filling prescriptions – they provide trusted advice, personalized support and a vast range of services.”

The debut of myWalgreens marks another milestone in the company’s digital transformation. Walgreens delivers customers more and more benefits and a highly-personalized experience by working with the very best technology and customer-insight partners, including Microsoft, Adobe and Epsilon.

Online or on the app, myWalgreens members can:

Save Time and Increase Convenience

  • Shop a full assortment of more than 27,000 items, including everyday health and wellness and over-the-counter essentials, as well as photos
  • Add a payment method to their digital wallet for faster contactless checkout
  • Redeem Walgreens Cash rewards instantly at checkout
  • Choose digital receipts for quick contactless checkout and to track purchases

Stay Healthy

  • Earn bonus Walgreens Cash rewards for achieving health goals
  • Receive daily, personalized recommendations for health and wellness, as well as real-time local environment and health forecasts

Help Communities

  • Donate their Walgreens Cash rewards to charity (the eligible charity organizations will rotate, beginning with the Full Plate Project, a program of Comic Relief U.S.’ Red Nose Day which works to end child poverty)

Starting today, current Walgreens Balance Rewards members can transfer their membership to myWalgreens at mywalgreens.com. Current Balance Rewards members have until January 31, 2021 to sign up for myWalgreens to ensure that existing rewards roll over to the new program. Over the next several months, myWalgreens will announce even more benefits for customers and patients.

Click here for myWalgreens press kit, including a logo, images and app screenshots.

About Walgreens

Walgreens (www.walgreens.com) is included in the Retail Pharmacy USA Division of Walgreens Boots Alliance, Inc. (Nasdaq: WBA), a global leader in retail and wholesale pharmacy. As America’s most loved pharmacy, health and beauty company, Walgreens purpose is to champion the health and wellbeing of every community in America. Operating more than 9,000 retail locations across America, Puerto Rico and the U.S. Virgin Islands, Walgreens is proud to be a neighborhood health destination serving approximately 8 million customers each day. Walgreens pharmacists play a critical role in the U.S. healthcare system by providing a wide range of pharmacy and healthcare services. To best meet the needs of customers and patients, Walgreens offers a true omnichannel experience, with platforms bringing together physical and digital, supported by the latest technology to deliver high-quality products and services in local communities nationwide.

* As compared to national omni-channel food and pharmacy mass retailers that offer store pick-up free-of-charge.

** For Walgreens store locations that are not open 24 hours, orders must be placed at least one hour prior to store closing in order to be eligible. Otherwise, order will be ready the following business day. Customer will be notified via email when order is ready for pickup and will be provided instructions for a drive-up experience that complies with social distancing guidelines. Orders are not guaranteed to be ready within the 30-minute time window and may be subject to change or substitution depending on product availability at the time order is placed. Orders with age-restricted items may only be picked up in store. Prescription orders not eligible but may be ordered through Walgreens Express®. To find the location and hours of a Walgreens store near you, visit Walgreens.com/FindAStore.

Walgreens PR Contact:

Emily Hartwig-Mekstan

[email protected]

 

Walgreens Boots Alliance PR Contact:

Morry Smulevitz

[email protected]

 

Investor Relations:

+1-847-315-2922

 

http://news.walgreens.com

@WalgreensNews

facebook.com/Walgreens

KEYWORDS: Illinois United States North America

INDUSTRY KEYWORDS: Technology Discount/Variety Men Family Fitness & Nutrition Consumer Supermarket Health Food/Beverage Cosmetics Retail Women Pharmaceutical Convenience Store Seniors Consumer Electronics Online Retail

MEDIA:

Photo
Photo
Home Screen (Graphic: Business Wire)
Photo
Photo
Walgreens pickup at photo counter (Photo: Business Wire)
Photo
Photo
Walgreens pickup sign (Photo: Business Wire)
Photo
Photo
myWalgreens (Graphic: Business Wire)
Photo
Photo
Walgreens pickup at curbside (Photo: Business Wire)
Photo
Photo
myWalgreens app at pickup (Photo: Business Wire)
Photo
Photo
Walgreens pickup at curbside sign (Photo: Business Wire)
Photo
Photo
Health alert example (Graphic: Business Wire)
Posted on

FedEx Express Strengthens Operations and Services with Opening of New Ramp at Ontario International Airport

FedEx Express Strengthens Operations and Services with Opening of New Ramp at Ontario International Airport

MEMPHIS, Tenn.–(BUSINESS WIRE)–
FedEx Express, a subsidiary of FedEx Corp. (NYSE: FDX) and one of the world’s largest express transportation companies, announced today the opening of its new state-of-the-art ramp operation located at Ontario International Airport in Ontario, Calif. The opening comes before what’s expected to be a record-setting holiday shipping season and is part of the company’s plan to increase operational efficiencies and to meet growing customer demands.

“The opening of our new FedEx Express Ontario ramp positions our operations and services to efficiently handle the growing e-commerce volume coming out of Southern California and strengthens our competitive position in the market,” said Richard W. Smith, Regional President of The Americas and EVP of Global Support, FedEx Express. “FedEx launched operations at Ontario International Airport 33 years ago, and we’re proud to have reached this new milestone as we continue to transform our network for what’s next.”

The 59.5-acre site includes a 251,000-square-foot, two-story facility with an automated sort of up to 12,000 packages per hour, including more than 2,700 non-conveyable shipments. The facility will staff 490 team members and includes nine wide-body aircraft gates, 14 feeder aircraft gates and 18 truck docks.

About FedEx Express

FedEx Express is one of the world’s largest express transportation companies, providing fast and reliable delivery to more than 220 countries and territories. FedEx Express uses a global air-and-ground network to speed delivery of time-sensitive shipments, by a definite time and date with a money-back guarantee.

About FedEx Corp.

FedEx Corp. (NYSE: FDX) provides customers and businesses worldwide with a broad portfolio of transportation, e-commerce and business services. With annual revenue of $71 billion, the company offers integrated business solutions through operating companies competing collectively, operating collaboratively and innovating digitally under the respected FedEx brand. Consistently ranked among the world’s most admired and trusted employers, FedEx inspires its more than 500,000 team members to remain focused on safety, the highest ethical and professional standards and the needs of their customers and communities. To learn more about how FedEx connects people and possibilities around the world, please visit about.fedex.com.

Jonathan Lyons

FedEx Express Communications

901-355-5306

[email protected]

KEYWORDS: Tennessee United States North America Canada

INDUSTRY KEYWORDS: Other Transport Trucking Logistics/Supply Chain Management Air Transport

MEDIA:

Logo
Logo
Posted on

Veteran Software Executive Rajesh “Nat” Natarajan Joins RingCentral to Lead Product and Engineering

Veteran Software Executive Rajesh “Nat” Natarajan Joins RingCentral to Lead Product and Engineering

BELMONT, Calif.–(BUSINESS WIRE)–RingCentral, Inc. (NYSE: RNG), a leading provider of global enterprise cloud communications, collaboration, and contact center solutions, today announced that Nat Natarajan will join the company as its Executive Vice President of Products and Engineering. Natarajan, who joins from Ancestry where he was Chief Product Officer and Chief Technology Officer, will be responsible for leadership of RingCentral’s products, engineering, cloud operations, IT, and security teams.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20201119005493/en/

Nat Natarajan, courtesy of RingCentral

Nat Natarajan, courtesy of RingCentral

Natarajan brings more than 20 years of experience as a global operations, product, technology, and organizational leader. He has a reputation for developing highly innovative products, building successful and high-performing teams, and spearheading results-driven transformational change. As Executive Vice President and Chief Product and Technology Officer at Ancestry, Natarajan led a team responsible for product development, engineering, data science and technology strategy and implementation. He led the company’s digital transformation, increasing the pace of innovation and moving Ancestry’s 23+ petabytes of data to the cloud, unlocking Artificial Intelligence (AI) and Machine Learning (ML) capabilities to deliver smart, personalized experiences to millions of customers globally.

Prior to Ancestry, Natarajan was Senior Vice President, Chief Product and Technology Officer for Intuit’s TurboTax, where he was responsible for product innovation that included driving broad customer adoption of their mobile apps. He was also the company’s Chief Information Security and Fraud Officer, where he led the development of the companywide vision and strategy for information security. Before Intuit, Natarajan held multiple senior roles at PayPal, including Vice President of Global Product Development and Vice President of Platform Engineering and Operations.

“It is my pleasure to welcome Nat to RingCentral. Nat brings deep product and technology expertise combined with a customer-centric approach that aligns perfectly with our philosophy at RingCentral and the opportunity ahead supporting a world of ‘Work from Anywhere,’” said Anand Eswaran, President and Chief Operating Officer at RingCentral. “RingCentral has always had a clear focus on bringing the latest communications innovation to enterprises globally. Nat brings deep expertise in cloud computing, security, and reaching communities and users at scale. His experience and product leadership at Ancestry, Intuit and PayPal, where user-centric innovation velocity was critical in making a difference to people every day, is a great asset for the innovation journey ahead at RingCentral.”

“I am excited with the opportunity to help deliver innovations to enterprises globally as they go through their digital transformation to enable everyone productively working from anywhere,” said Natarajan. “The concept of the workplace is evolving, and RingCentral has been at the forefront of this movement with a proven track record of success in enabling businesses of all sizes to effectively communicate and collaborate, from anywhere, in any mode, and on any device. The company’s leadership in the industry is a testament to the success of the product, and I look forward to building upon the great work the team has already done to further accelerate innovation and help cement RingCentral’s industry position for the future.”

Kira Makagon, RingCentral’s Executive Vice President and Chief Innovation Officer, will partner closely with Natarajan during his onboarding, before taking on her next challenge, creating and leading RingCentral’s new strategic initiative – RingCentral Ventures. RingCentral Ventures will aim to be an active strategic partner working with talented startups across a number of disciplines with the goal of fostering innovation, enhanced user experiences, and further productivity improvements as enterprises worldwide are bringing all their communications to the cloud as part of their digital transformation initiatives. RingCentral Ventures is planned to be launched in 2021.

“I am excited to welcome a leader of Nat’s caliber to RingCentral. RingCentral’s goal is to enable enterprises worldwide to transition their communications infrastructure to the cloud, while benefiting from enhanced functionality, reliability, security, and employee productivity. This is especially timely and critical given the latest employee mobility and work-from-anywhere trends. We’re delighted to welcome Nat to the team to help lead the next chapter in RingCentral’s innovation and technology leadership,” said Vlad Shmunis, Founder, Chairman and CEO of RingCentral. “I also want to thank our Chief Innovation Officer, Kira Makagon, for her tireless dedication, leadership and vision, which have been paramount to RingCentral’s success to date. I very much look forward to her continued impact to RingCentral, and industry as a whole, as she launches and leads RingCentral Ventures to partner with the startup community so as to help bring the latest thinking and technology innovation to our customers.”

About RingCentral

RingCentral, Inc. (NYSE: RNG) is a leading provider of cloud Message Video Phone™ (MVP™), customer engagement and contact center solutions for businesses worldwide. More flexible and cost effective than legacy on-premise PBX and video conferencing systems that it replaces, RingCentral empowers modern mobile and distributed workforces to communicate, collaborate, and connect via any mode, any device, and any location. RingCentral’s open platform integrates with leading third party business applications and enables customers to easily customize business workflows. RingCentral is headquartered in Belmont, California, and has offices around the world.

© 2020 RingCentral, Inc. All rights reserved. RingCentral, Message Video Phone, MVP and the RingCentral logo are trademarks of RingCentral, Inc.

Mariana Leventis

[email protected]

650-562-6545

KEYWORDS: California United States North America

INDUSTRY KEYWORDS: VoIP Mobile/Wireless Technology Telecommunications Software

MEDIA:

Logo
Logo
Photo
Photo
Nat Natarajan, courtesy of RingCentral
Posted on

Fiserv Enables ExxonMobil to Facilitate Commerce Within Google Pay App

Fiserv Enables ExxonMobil to Facilitate Commerce Within Google Pay App

Businesses can extend their omnichannel commerce capabilities to new and existing payment channels, including Google Pay, via a single platform from Fiserv

ExxonMobil is leveraging Fiserv to enable new touchless payment experiences at the pump via Google Pay

BROOKFIELD, Wis.–(BUSINESS WIRE)–Fiserv, Inc. (NASDAQ: FISV), a leading global provider of payments and financial services technology solutions, today announced it is enabling ExxonMobil to deliver a new omnichannel commerce experience within the enhanced Google Pay mobile application.

As announced by Google on November 18, ExxonMobil has launched a new contactless payment capability that enables consumers to utilize Google Pay to digitally pay at the pump, either by scanning a QR-code on the pump or by activating the pump from within the Google Pay app on iOS or Android. The commerce experience – pump activation, payment tokenization, payment processing, and digital receipt delivery – is powered by omnichannel commerce technology from Fiserv. Payments are made via a consumer’s existing Google Pay account; no additional application download or separate account is required.

“We designed Google Pay to help consumers and merchants engage and transact more conveniently and securely,” said Josh Woodward, Director, Google Pay. “The new Google Pay platform gives consumers a way to pay easily at their favorite merchants and it creates opportunities for merchants to deepen customer engagement in creative ways with offers, rewards, and customized, dynamic content.”

By combining new innovation with their existing payment relationship with Fiserv, businesses like ExxonMobil are able to easily connect to Google Pay utilizing the same rails for payment authorization and settlement that Fiserv already leverages to serve the merchant’s brick-and-mortar locations and digital footprint.

“With consumers increasingly turning to contactless payment, we’re excited to offer yet another convenient, secure way to pay at Exxon and Mobil stations,” said Eric Carmichael, Americas fuels marketing manager at ExxonMobil. “As more people get back on the road, we’re offering a variety of ways to pay at the pump while reducing contact, and ultimately providing a better fueling experience.”

Leveraging the Carat Omnichannel Commerce Ecosystem

Businesses like ExxonMobil are enabling their omnichannel commerce strategies via the Carat ecosystem from Fiserv, which securely delivers limitless payment opportunities across the most popular channels and devices. Through simple API access, Carat enables businesses like ExxonMobil, experience providers and financial institutions to imagine and realize new customer experiences.

“Fiserv is helping organizations span digital and physical payments to create the true omnichannel commerce experience that today’s consumer is demanding,” said Nandan Sheth, head of Global Digital Commerce at Fiserv. “Carat connects businesses to the places and ways people want to transact.”

In a world that is moving faster than ever before, Fiserv helps clients deliver solutions that are in step with the way people live and work today – financial services at the speed of life. Learn more at fiserv.com.

Additional Resources:

About Fiserv

Fiserv, Inc. (NASDAQ: FISV) aspires to move money and information in a way that moves the world. As a global leader in payments and financial technology, the company helps clients achieve best-in-class results through a commitment to innovation and excellence in areas including account processing and digital banking solutions; card issuer processing and network services; payments; e-commerce; merchant acquiring and processing; and the Clover® cloud-based point-of-sale solution. Fiserv is a member of the S&P 500® Index and the FORTUNE® 500, and is among FORTUNE World’s Most Admired Companies®. Visit fiserv.com and follow on social media for more information and the latest company news.

FISV-G

Media Relations:

Chase Wallace

Director, Communications

Fiserv, Inc.

+1 404-890-2132

[email protected]

Additional Contact:

Ann S. Cave

Vice President, External Communications

Fiserv, Inc.

678-325-9435

[email protected]

KEYWORDS: Wisconsin United States North America

INDUSTRY KEYWORDS: Finance Internet Professional Services Mobile/Wireless Technology

MEDIA:

Logo
Logo
Posted on

Facedrive’s TraceSCAN to Offer Global Contact-Tracing Services Powered by Microsoft Azure

 Facedrive’s TraceSCAN to Offer Global Contact-Tracing Services Powered by Microsoft Azure

TORONTO–(BUSINESS WIRE)–
Facedrive Inc. (“Facedrive”) (TSXV: FD) a Canadian “people-and-planet first” tech ecosystem is pleased to announce that its contact-tracing platform TraceSCAN is completing cloud migration process to power its solution through Microsoft Azure. The move marks the first step in a collaboration between the two companies, which will allow businesses and individuals around the world to easily avail of TraceSCAN’s advanced COVID-19 contact-tracing wearable solution and extend to Microsoft’s enterprise cloud applications through its partner network.

TraceSCAN wearables were created in an effort to offer ongoing frontline assistance in response to the COVID-19 pandemic through a joint effort between Facedrive Health and a group of researchers from the University of Waterloo in April 2020. It has subsequently developed a unique Bluetooth wearable technology integration, been endorsed by the Government of Ontario, and started implementation with multiple large employers as they practice safe return-to-work policies in environments where the use of mobile devices is restricted. As outlined in a Privacy White Paper released in collaboration with MT>Ventures on June 4, 2020 (https://www.businesswire.com/news/home/20200604005310/en/Facedrive-Health-releases-“TraceSCAN”-Privacy-White-Paper-in-collaboration-with-MT-Ventures), TraceSCAN has comprehensive safeguards put in place in order to ensure user data privacy and security, such as robust encryption carried out both at rest and in transit, rotating temporary anonymous identifiers, etc. It also explains how the TraceSCAN privacy compliance framework is underpinned by the ten Fair Information Practice Principles (or FIPPs) set out in the Personal Information Protection and Electronic Documents Act (PIPEDA). The White Paper is publicly available and can be requested from the official TraceSCAN website at www.tracescan.ca.

TraceSCAN is a standalone contact-tracing wearable solution that is built around the most advanced Bluetooth technology. The wearable devices exchange encrypted ID’s when they are in close proximity. Users can upload their contact history periodically to Azure through kiosks that are located at the entrances and exits of participating organizations. The kiosks are also powered by Microsoft’s Surface Go 2 tablets, hence providing a complete end-to-end data transfer solution hosted on Azure.

Several months after its launch and following multiple successful implementations in Canada, TraceSCAN is now ready to extend its services to more businesses and individuals globally, and believes that Azure will benefit them by accurately and securely harnessing the data with the customer’s privacy as top priority. Azure will power the TraceSCAN platform by ensuring access to one of the largest cloud footprints available today, along with data sovereignty, hybrid capabilities, and advanced developer and data services. In addition, Facedrive and Microsoft plan to explore synergies resulting from integration, such as opportunities for TraceSCAN to use the capabilities of Azure IoT Hub, Azure IoT Central, Azure Sphere and other potential fits to use advanced workloads within Azure and connect contact-tracing data with business processes and analytics while keeping customer privacy at the forefront. Furthermore, as the collaboration evolves, more collaboration avenues may open through Microsoft’s extensive partner network, thus increasing reach of the TraceSCAN products tremendously.

“Microsoft Azure and the Microsoft Partner Network provides us with a great launchpad for our growth and expansion plans globally,” said Sayan Navaratnam, Chairman and CEO of Facedrive. “We are excited to drive this collaboration for the safety, health and well-being of thousands, if not millions of workers and their families as businesses return to work in these unprecedented circumstances,” added Navaratnam.

“Innovative companies like TraceSCAN are using the power of Microsoft Azure to help reduce the spread of COVID, while maintaining privacy for users,” said Suzanne Gagliese, GM of Microsoft One Commercial Partner Canada. “Microsoft is committed to helping partners like TraceSCAN deliver solutions that will allow customers to focus more on their core businesses. TraceSCAN’s use of our open-source cloud solution to innovate while prioritizing security and compliance is the kind of innovation that will help fuel our economic recovery.”

FOR CONSIDERATION

About Facedrive

Facedrive is a multi-faceted “people-and-planet first” tech ecosystem offering socially-responsible services to local communities with a strong commitment to doing business fairly, equitably and sustainably. As part of this commitment, Facedrive’s vision is to fulfil its mandate through a number of verticals that either leverage existing technologies of the Company or project considerable synergies with existing lines of business (the “Facedrive Verticals”). The Facedrive Verticals include its: rideshare business (“Facedrive Rideshare”), sustainable e-commerce platform (“Facedrive Marketplace”), food-delivery service (“Facedrive Foods”), social media platform (“Facedrive Social”), andits contact-tracing and sustainable health services business (“Facedrive Health”).

Facedrive Rideshare was the first to offer green transportation solutions in the TaaS space, planting thousands of trees based on user consumption and offering choices between electric vehicles (including on a subscription basis), hybrid vehicles and conventional vehicles. Facedrive Marketplace offers curated merchandise created from sustainably sourced materials. Facedrive Foods offers contactless deliveries of a wide variety of foods with the focus on delivering healthy foods right to consumers’ doorsteps. Facedrive Social strives to keep people connected in a physically-distanced world through its HiQ socialization platform that invites users to interact based on common interests on its communication platform, which offers gamification features. Facedrive Health strives to develop and offer innovative technological solutions to the most acute health challenges including its proprietary TraceSCAN wearable technology for contact tracing. Facedrive envisions changing the ridesharing, food delivery, e-commerce, social and health tech narratives for the better, for everyone.

For more about Facedrive, visit www.facedrive.com.

Forward-Looking Statements

Certain information in this press release contains forward-looking information. This information is based on management’s reasonable assumptions and beliefs in light of the information currently available to us and are made as of the date of this press release. Actual results and the timing of events may differ materially from those anticipated in the forward-looking information as a result of various factors. Information regarding our expectations of future results, performance, achievements, prospects or opportunities or the markets in which we operate is forward-looking information. Statements containing forward-looking information are not facts but instead represent management’s expectations, estimates and projections regarding future events or circumstances. Many factors could cause our actual results, level of activity, performance or achievements or future events or developments to differ materially from those expressed or implied by the forward-looking statements.

See “Forward-Looking Information” and “Risk Factors” in the Corporation’s Filing Statement dated August 28, 2019 for a discussion of the uncertainties, risks and assumptions associated with these statements. Readers are urged to consider the uncertainties, risks and assumptions carefully in evaluating the forward-looking information and are cautioned not to place undue reliance on such information. We have no intention and undertake no obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by applicable securities law.

Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

View source version on businesswire.com: https://www.businesswire.com/news/home/20191205005428/en/

Media: Sana Srithas | [email protected]

Sayan Navaratnam

Chief Executive Officer and Director

Tel: 1-888-300-2228

KEYWORDS: North America Canada

INDUSTRY KEYWORDS: Health Infectious Diseases Environment Technology Software General Health Networks

MEDIA:

Logo
Logo
Posted on

Twist Bioscience and Biotia Announce Research Use Only Availability of First Hybridization Capture-Based Next-Generation Sequencing SARS-CoV-2 Assay for Characterization and Surveillance of the Virus

Twist Bioscience and Biotia Announce Research Use Only Availability of First Hybridization Capture-Based Next-Generation Sequencing SARS-CoV-2 Assay for Characterization and Surveillance of the Virus

— Data from Research Use Only Assay and Software Presented at Infectious Disease Week 2020 —

SOUTH SAN FRANCISCO, Calif. & NEW YORK–(BUSINESS WIRE)–
Twist Bioscience Corporation (NASDAQ: TWST), a company enabling customers to succeed through its offering of high-quality synthetic DNA using its silicon platform, and Biotia, Inc., a company that uses proprietary analytical software for infectious disease diagnostics, today announced the availability of an important new research tool for the sequencing and surveillance of COVID-19.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20201119005413/en/

The companies have developed the SARS-CoV-2 Next-Generation Sequencing (NGS) Assay, an NGS-based assay for research-use only (RUO). The SARS-CoV-2 NGS RUO Assay is a highly sensitive nucleic acid hybridization capture-based assay used for the detection, characterization, and environmental monitoring of the SARS-CoV-2 virus. It utilizes Twist Bioscience’s unique ability to rapidly develop virus-specific panels by DNA synthesis and Biotia’s comprehensive data analysis software and reporting capabilities.

The SARS-CoV-2 NGS Assay was validated on a NextSeq® sequencer and identifies all SARS-CoV-2 nucleic acid sequences, to allow for surveillance of how the genetic sequence of the virus is changing. In contrast, a majority of SARS-CoV-2 tests based on polymerase chain reaction (PCR) only identify limited genetic markers of the virus. A recent study compared the performance of three different commercially available NGS library preparation kits confirming that hybridization capture results in more even coverage across all sequences in a sample when compared to PCR-based NGS assays. In addition, the SARS-CoV-2 NGS Assay reports the full sequence of the virus, enabling improved understanding of mutations, genetic variations and the evolution of the virus as it is transmitted.

“While there are many available high-throughput diagnostic tests available for COVID-19, our solution provides sequence data that enables researchers the ability to sequence and surveil the evolution of mutations in the virus over time and geography,” said Emily M. Leproust, Ph.D., CEO and co-founder of Twist Bioscience. “Importantly, while many labs are conducting individual sequencing runs for each patient sample, this assay and the accompanying software provide a way to batch about 100 patient samples together, providing actionable information that can then be used to inform public health particularly as we see second and third waves of COVID escalating.”

“We are fortunate to be in a position where we can devote our time and resources to fight this global pandemic,” commented Niamh O’Hara, Ph.D., CEO and co-founder of Biotia. “This novel and insightful COVID-19 solution is an important step to make NGS-based infectious disease surveillance more widely available and to advance COVID-19 research and control.”

Biotia presented data from the assay at the Infectious Disease Week (IDWeek) 2020 Annual Meeting that identify 124 genetic mutations not previously described, including 26 in the functionally important spike protein of SARS-CoV-2. The end-to-end solution was validated on 120 clinical samples (60 positive, 60 negative), and confirmed that the SARS-CoV-2 NGS Assay powered by the COVID-DX Software could be used to detect viral RNA in laboratory research settings. It also provided insight into genetic variants to track transmission, identify risk, and predict outcome and therapeutic response. [Nagy-Szakal et al., SARS-CoV-2 NGS Assay Powered by Biotia COVID-DX Software, IDWeek 2020]

“This test spans both diagnostic methods and vaccine research,” noted Christopher Mason, Ph.D., co-founder of Biotia, “We believe this end-to-end solution brings needed tools into the fight against COVID-19, as well as pioneering these capture methods for tracking other pathogens in the future.”

About the Solution

The SARS-CoV-2 NGS Assayis an RUO end-to-end solution intended for the quantitative detection of the SARS-CoV-2 virus from nasopharyngeal (NP), oropharyngeal (OP), anterior nasal and mid-turbinate nasal swabs as well as from nasopharyngeal wash/aspirates, nasal aspirates and bronchoalveolar lavage (BAL) specimens from individuals. The SARS-CoV-2 NGS Assay, which includes Twist Bioscience’s SARS-CoV-2 synthetic RNA controls, detects all strains of SARS-CoV-2 in samples with as few as 800 viral copies per milliliter.

The complementary Biotia COVID-DX software provides an RUO report including the presence or absence of SARS-CoV-2 virus, the full sequence of the virus, genetic variants and phylogenetic analysis. FASTQ files (sequencing output) can be generated in laboratories nationwide and submitted to Biotia COVID-DX (v1.0), a cloud-based software to generate RUO reports. Access to the Biotia COVID-DX software is provided through a unique order number emailed to a researcher that includes credits for each kit purchased.

About Biotia

Biotia is a health tech company located in New York, NY that leverages sequencing-based technology and proprietary AI-powered software to rapidly and accurately identify microorganisms and antimicrobial resistance. Their mission is to fight infectious disease by deploying the leading reference library of microbes worldwide. Biotia, a spinout company of Jacobs Technion-Cornell Institute at Cornell Tech has a New York State CLIA lab for COVID-19 testing affiliated with SUNY Downstate Health Sciences University.

Follow us on Twitter | Facebook | LinkedIn

About Twist Bioscience Corporation

Twist Bioscience is a leading and rapidly growing synthetic biology and genomics company that has developed a disruptive DNA synthesis platform to industrialize the engineering of biology. The core of the platform is a proprietary technology that pioneers a new method of manufacturing synthetic DNA by “writing” DNA on a silicon chip. Twist is leveraging its unique technology to manufacture a broad range of synthetic DNA-based products, including synthetic genes, tools for next-generation sequencing (NGS) preparation, and antibody libraries for drug discovery and development. Twist is also pursuing longer-term opportunities in digital data storage in DNA and biologics drug discovery. Twist makes products for use across many industries including healthcare, industrial chemicals, agriculture and academic research.

Follow us on Twitter | Facebook | LinkedIn | YouTube

Legal Notice Regarding Forward-Looking Statements

This press release contains forward-looking statements. All statements other than statements of historical facts contained herein, including without limitation, the ability of the SARS-CoV-2 NGS Assay to successfully advance COVID-19 research and control, are forward-looking statements reflecting the current beliefs and expectations of management made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Such forward-looking statements involve known and unknown risks, uncertainties, and other important factors that may cause Twist Bioscience’s actual results, performance, or achievements to be materially different from any future results, performance, or achievements expressed or implied by the forward-looking statements. Such risks and uncertainties include, among others, the risks and uncertainties of the ability to attract new customers and retain and grow sales from existing customers; risks and uncertainties of rapidly changing technologies and extensive competition in synthetic biology could make the products Twist Bioscience is developing obsolete or non-competitive; scientific unknowns and new information relating to the SARS-CoV-2 virus; the duration, extent and impact of the COVID-19 pandemic; supply chain and other disruptions caused by the COVID-19 pandemic or otherwise; uncertainties of the retention of a significant customer; risks of third party claims alleging infringement of patents and proprietary rights or seeking to invalidate Twist Bioscience’s patents or proprietary rights; and the risk that Twist Bioscience’s proprietary rights may be insufficient to protect its technologies. For a further description of the risks and uncertainties that could cause actual results to differ from those expressed in these forward-looking statements, as well as risks relating to Twist Bioscience’s business in general, see Twist Bioscience’s risk factors set forth in Twist Bioscience’s Quarterly Report on Form 10-Q filed with the Securities and Exchange Commission on August 12, 2020. Any forward-looking statements contained in this press release speak only as of the date hereof, and Twist Bioscience specifically disclaims any obligation to update any forward-looking statement, whether as a result of new information, future events or otherwise.

Twist Bioscience Investor Contact:

Argot Partners

Maeve Conneighton

212-600-1902

[email protected]

Twist Bioscience Media Contact:

Angela Bitting

925- 202-6211

[email protected]

Biotia Media Contact:

Steve Capoccia

617-372-1539

[email protected]

KEYWORDS: California New York United States North America

INDUSTRY KEYWORDS: Data Management Other Health Technology Nanotechnology General Health Medical Devices Infectious Diseases Genetics Other Technology Science Biotechnology Software Other Science Health Research

MEDIA:

Logo
Logo
Logo
Logo
Posted on

CommScope Launches the ARRIS SURFboard S33 Cable Modem

CommScope Launches the ARRIS SURFboard S33 Cable Modem

Introducing the Next Generation of SURFboard DOCSIS Modems

HICKORY, N.C.–(BUSINESS WIRE)–
CommScope today announced the launch of the ARRIS SURFboard S33 DOCSIS 3.1 multi-Gigabit cable modem, now available in the United States. As the newest modem in the SURFboard family, the S33 is perfect for customers who want to upgrade and future-proof their home network for the best performance.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20201119005319/en/

With a 2.5 Gigabit per second (Gbps) Ethernet port plus a second 1 Gbps Ethernet port, CommScope's ARRIS SURFboard S33 cable modem is capable of providing a total throughput of up to 3.5 Gbps, powering the most advanced home networks and enabling simultaneous video conferencing, multiple 4K ultra-HD video streams and online gaming sessions with confidence. (Photo: Business Wire)

With a 2.5 Gigabit per second (Gbps) Ethernet port plus a second 1 Gbps Ethernet port, CommScope’s ARRIS SURFboard S33 cable modem is capable of providing a total throughput of up to 3.5 Gbps, powering the most advanced home networks and enabling simultaneous video conferencing, multiple 4K ultra-HD video streams and online gaming sessions with confidence. (Photo: Business Wire)

With a 2.5 Gigabit per second (Gbps) Ethernet port plus a second 1 Gbps Ethernet port, the SURFboard S33 cable modem is capable of providing a total throughput of up to 3.5 Gbps, powering the most advanced home networks and enabling simultaneous video conferencing, multiple 4K ultra-HD video streams and online gaming sessions with confidence.

“Connectivity enables our busy digital lives and drives our economy; however, with more people working and learning from home, it has become more important than ever,” said Evan Groat, Senior Vice President, Retail Products, CommScope. “By deploying the SURFboard S33 cable modem in the home, customers can be confident knowing they are getting world class speeds and value from their cable internet plan.”

Faster speeds and reduced buffering

The SURFboard S33 delivers a total of up to 3.5 Gbps throughput to a home network. This enables customers with even the highest speed broadband subscription plans to get the most use of their plans and less buffering.

Easy set up

The SURFboard S33 is the best cable modem for Gigabit and multi-Gigabit cable internet speed plans. It is certified for use on all major service providers in the United States, and it is easy to set up. All a customer has to do is make several simple connections to the unit, check their service provider’s activation website and the S33 will be up and running.

Compact, powerful new design

The SURFboard S33 features the next generation design for SURFboard DOCSIS products. While maintaining its compact size (5.1 in × 1.8 in × 4.7 in), the SURFboard S33 shows off its sleek, industrial design from CommScope. The SURFboard S33’s multi-Gigabit speeds can power a customer’s home network and fit into any networking space.

Pricing and availability

  • SURFboard S33 cable modem: $179.99 MSRP.
  • Available at Best Buy and SURFboard.com

Two-year warranty

The SURFboard S33 cable modem comes with a two-year warranty and dedicate support line for customers—1-877-466-8646. With this warranty, customers are ensured the SURFboard S33 cable modem deployed in their home or office network is covered.

All product names, trademarks and registered trademarks are property of their respective owners.

About CommScope:

CommScope (NASDAQ: COMM) is pushing the boundaries of technology to create the world’s most advanced wired and wireless networks. Our global team of employees, innovators and technologists empower customers to anticipate what’s next and invent what’s possible. Discover more at www.commscope.com.

Follow us on Twitter and LinkedIn and like us on Facebook.

Sign up for our press releases and blog posts.

About ARRIS SURFboard

ARRIS SURFboard products are your gateway to entertainment. They let you enjoy the latest entertainment, world class speeds, and the coolest new services throughout your home, and beyond. And they’re available at your favorite retail store. For more information, visit https://www.surfboard.com/.

*DOCSIS 3.1 is a CableLabs standard for high speed internet access that defines support for up to 10 Gbps downstream and 1 Gbps upstream. Actual cable operator network speeds will vary and will be less than the calculated maximum possible speeds. Actual upload and download speeds are affected by several factors including, but not limited to: the capacity of your cable operator’s network, the services offered by your cable operator, cable and Internet network traffic, your computer equipment, type and capacity of your internet servers, number of connections to your Internet servers, and availability of internet router(s). DOCSIS 3.0 or DOCSIS 3.1 cable Internet service required. Internet capable gaming console required for gaming experience. While this modem supports the DOCSIS® 3.1 specifications and is backward compatible to DOCSIS® 3.0, it does not support the maximum possible DOCSIS® 3.1 speeds. The S33 has one 1-Gigabit Ethernet port and one 2.5-Gigabits Ethernet port, delivering a total of 3.5 Gbps transfer rate to your home network, thereby limiting the throughput from the cable operator network. Your total throughput from your cable operator using this modem will not exceed 3.5 Gbps.

This press release includes forward-looking statements that are based on information currently available to management, management’s beliefs, as well as on a number of assumptions concerning future events. Forward-looking statements are not a guarantee of performance and are subject to a number of uncertainties and other factors, which could cause the actual results to differ materially from those currently expected. In providing forward-looking statements, the company does not intend, and is not undertaking any obligation or duty, to update these statements as a result of new information, future events or otherwise.

Source: CommScope

News Media Contact:

Joseph P. Depa III, CommScope

+1 828-431-9803 or [email protected]

Financial Contact:

Kevin Powers, CommScope

+1-828-323-4970

KEYWORDS: North Carolina United States North America

INDUSTRY KEYWORDS: Telecommunications Networks Internet Hardware Data Management Consumer Electronics Technology Mobile/Wireless

MEDIA:

Logo
Logo
Photo
Photo
With a 2.5 Gigabit per second (Gbps) Ethernet port plus a second 1 Gbps Ethernet port, CommScope’s ARRIS SURFboard S33 cable modem is capable of providing a total throughput of up to 3.5 Gbps, powering the most advanced home networks and enabling simultaneous video conferencing, multiple 4K ultra-HD video streams and online gaming sessions with confidence. (Photo: Business Wire)
Photo
Photo
The CommScope ARRIS SURFboard S33 DOCSIS 3.1 multi-Gigabit cable modem is now available in the United States. As the newest modem in the SURFboard family, the S33 is perfect for customers who want to upgrade and future-proof their home network for the best performance. (Photo: Business Wire)
Posted on

Diversified Healthcare Trust Communities Receive National Recognition

Diversified Healthcare Trust Communities Receive National Recognition

30 Communities in SHOP Segment Featured on U.S. News and World Report’s Prestigious List

NEWTON, Mass.–(BUSINESS WIRE)–Diversified Healthcare Trust (Nasdaq: DHC) is pleased to announce that U.S. News and World Report, the global authority in health care rankings, has recognized 30 communities within DHC’s Senior Housing Operating Portfolio (SHOP) segment in its annual list of “Best Nursing Homes”. The list of the country’s best short-term rehabilitation and long-term care facilities reflects comprehensive information about care, health inspections and staffing, as well as other factors including COVID-19 management, flu and pneumonia vaccination rates, and infection control protocols.

“In light of the challenges presented by the pandemic, we are extremely pleased to have 30 of our communities managed by Five Star Senior Living recognized for providing exemplary resident safety and care,” said Jennifer Francis, President and Chief Operating Officer. “We strongly believe that Five Star prioritizing the well-being of current and prospective residents while providing an exceptional resident experience is critical to our residents and communities during these unprecedented times. Further, we believe that best-in-class recognition such as those received for these communities helps to reassert confidence in our senior living platform and in Five Star, which is paramount as we move forward.”

This year, the list was updated to include a patient summary that reflects COVID-19 data alongside other measurements. U.S. News and World Report also offers advice on choosing a community amidst the pandemic. All measures used by U.S. News and World Report were derived from publicly available data from Centers for Medicare and Medicaid Services as of August 2020. For more information regarding the methodology of the ratings, please click here. A full list of the Diversified Healthcare Trust communities managed by Five Star Senior Living Inc. featured on this year’s report include:

  • Pueblo Norte Senior Living Community (Arizona)
  • The Forum at Desert Harbor (Arizona)
  • The Gardens of Scottsdale (Arizona)
  • Remington Club Health Center (California)
  • La Villa Grande Care Center (Colorado)
  • Mantey Heights Rehabilitation and Care Center (Colorado)
  • Five Star Foulk Manor North (Delaware)
  • Forwood Manor (Delaware)
  • Millcroft (Delaware)
  • Shipley Manor (Delaware)
  • Barrington Terrace at Boynton Beach (Florida)
  • Forum at Deer Creek (Florida)
  • Park Summit at Coral Springs (Florida)
  • Stratford Court of Palm Harbor (Florida)
  • The Court at Palm Aire (Florida)
  • Savannah Square Health Center (Georgia)
  • Church Creek (Illinois)
  • Forum at The Crossing (Indiana)
  • Meadowood Health Pavilion (Indiana)
  • The Forum at Overland Park (Kansas)
  • The Forum at Brookside (Kentucky)
  • Leisure Park Health Center (New Jersey)
  • The Montebello on Academy (New Mexico)
  • Healthcare Center at The Forum (Ohio)
  • Myrtle Beach Manor (South Carolina)
  • Healthcare Center at The Forum at Park Lane (Texas)
  • The Forum at Lincoln Heights (Texas)
  • The Forum at Memorial Woods Healthcare Center (Texas)
  • The Gardens of Bellaire (Texas)
  • Mitchell Manor – West Allis (Wisconsin)

Diversified Healthcare Trust (Nasdaq: DHC) is a real estate investment trust (REIT) focused on owning high-quality healthcare properties located throughout the United States. DHC seeks diversification across the health services spectrum: by care delivery and practice type, by scientific research disciplines, and by property type and location. As of September 30, 2020, DHC’s $8.2 billion portfolio included 407 properties in 37 states and Washington, D.C., occupied by more than 600 tenants, and totaling approximately 12 million square feet of medical office and life science properties and more than 30,000 living units. DHC is managed by the operating subsidiary of The RMR Group Inc., an alternative asset management company that is headquartered in Newton, MA. To learn more about DHC, visit www.dhcreit.com.

A Maryland Real Estate Investment Trust with transferable shares of beneficial interest listed on the Nasdaq.

No shareholder, Trustee or officer is personally liable for any act or obligation of the Trust.

Michael Kodesch, Director, Investor Relations

(617) 796-8234

www.dhcreit.com

KEYWORDS: Massachusetts United States North America

INDUSTRY KEYWORDS: Commercial Building & Real Estate Nursing Construction & Property Hospitals REIT Physical Therapy Managed Care Health Residential Building & Real Estate

MEDIA:

Logo
Logo